The Readout Loud

Biotech veteran Clive Meanwell discusses his new obesity startup, Metsera, and competing with Wegovy and Zepbound. They also talk about Teledoc CEO's departure after 15 years, Teladoc's challenges post-COVID, and the future of obesity drug development.

Discussing Vertex's $13 billion deal, biotech's struggles, Dendreon's history, and gas prices impact. Exploring industry performance, market reflections, and a surprise announcement. Fond farewell to Damien with heartfelt tributes, banter, and technical discussions.

Oruka Therapeutics CEO Lawrence Klein discusses raising first round of financing and competing in inflammation space. Topics include ALS drug withdrawal, challenges in cancer vaccine development, GOP one drug for Parkinson's, biotech mega-rounds, and innovative technologies in medical advancements.

Expert Sarah Owermohle discusses the Supreme Court case affecting medication abortion and drug development. Topics include GLP-1 treatment debates, congressional ban on Chinese biotech, and celebrating the podcast's 300 episodes milestone.

CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos share insights at the STAT Breakthrough Summit East. Topics include gene therapy costs, GLP-1 story twists, and a pie contest. The discussion also covers the future of healthcare, interdisciplinary teamwork in research, innovative allergy treatments, and muscle growth potential with medication.

Bioethicist discusses ALS treatment dilemma, gene therapy challenges, CAR-T cancer treatments, & first drug for liver disease. Pi Day pie contest at STAT Boston HQ adds fun twist to the episode. Ethics of drug withdrawal explored in light of FDA's authority in drug approvals.

Exploring barriers to using life-saving tools in combating opioid overdose epidemic, trends in venture capital financing in the biotech industry, Novo Nordisk's promising oral medication for obesity, and the critical role of methadone and buprenorphine in reducing opioid deaths.

Exploring legal insider trading in the biotech industry, booming biotech stocks, advancements in obesity research, surge in biotech IPOs, rise of PIPE financing, investor concerns about fairness, and analysis of financial motivations in the industry.

Discussion on the legacy of AbbVie CEO Richard Gonzalez, fetal genome surgery insights, ethical dilemmas of genome editing in fetuses, and the contrasting opinions on industry impact vs. patient welfare in the pharmaceutical industry.

The podcast delves into the pharmaceutical industry's efforts to weaken legislation allowing Medicare to negotiate drug prices and its implications for the 2024 election. It also covers updates on Alnylam Pharmaceuticals' future, competition in the pain drug market, and Gilead Sciences' recent acquisition.